Table 1.
Demographics and characteristics of the cases with baseline CD4+ T cell count (N = 351).
| Variable | Overall (n = 351) | HIV-1 subtypes | p-Value | ||||
|---|---|---|---|---|---|---|---|
| CRF01_AE (n = 210) | CRF07_BC (n = 88) | CRF08_BC (n = 23) | CRF55_01B (n = 17) | B (n = 13) | |||
| Age, median (IQR), y | 42 (35, 52) | 43 (34.75, 55) | 43 (35, 50.75) | 40 (35, 45) | 37 (31.5, 45.5) | 42 (33, 46) | 0.3364 |
| Gender, n (%) | 0.1042 | ||||||
| Male | 264 (75.2) | 155 (73.8) | 66 (75.0) | 15 (65.2) | 17 (100.0) | 11 (84.6) | |
| Female | 87 (24.8) | 55 (26.2) | 22 (25.0) | 8 (34.8) | 0 | 2 (15.4) | |
| Delay of HAART initiation, median (IQR), d | 36 (17, 406) | 40.5 (18, 336) | 35 (15, 864.75) | 43 (24, 572) | 21 (13, 40) | 18 (7.5, 887.5) | 0.2646 |
| Time on HAART, median (IQR), d | 1,036 (529, 1,797) | 1,123.5 (674.5, 1,987.25) | 866.5 (409.75, 1,486.25) | 1,024 (551, 2,568) | 448 (313.5, 1,037) | 898 (416, 1,388) | 0.0011 |
| Plasma HIV-1 RNA (copies/mL), median (IQR) | 624 (493, 774) | 600 (484, 758.5) | 671.5 (537.25, 812) | 678 (485, 721) | 683 (528.5, 844.5) | 605 (479.5, 761) | 0.4477 |
| Baseline CD4+ T cell count, median (IQR) | 181 (61, 281) | 145 (29, 232.75) | 252.5 (156, 373.75) | 262 (185, 359) | 193 (52.5, 343.5) | 174 (36, 223.5) | <0.0001 |
| Baseline CD8+ T cell count, median (IQR) | 686 (370, 1,116) | 659.5 (348.5, 960.25) | 802 (415.75, 1,243.25) | 671 (0, 1,169) | 959 (691.5, 1339.5) | 585 (269, 922) | 0.0323 |
| Baseline CD4+/CD8+ T cell count, median (IQR) | 0.17 (0.0775, 0.32) | 0.14 (0.05, 0.2575) | 0.255 (0.13, 0.3725) | 0.27 (0.15, 0.3975) | 0.145 (0.0475, 0.385) | 0.195 (0.13, 0.2725) | <0.0001 |
| In-silico predictions of HIV-1 co-receptor usage, n (%) | <0.0001 | ||||||
| CCR5-using | 263 (74.9) | 138 (65.7) | 84 (95.5) | 22 (95.7) | 8 (47.1) | 11 (84.6) | |
| CXCR4-using | 88 (25.1) | 72 (34.3) | 4 (4.5) | 1 (4.3) | 9 (52.9) | 2 (15.4) | |
Data are presented as no. (%).
HAART, Highly active antiretroviral therapy; NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTIs, Non-nucleoside reverse transcriptase inhibitors.